PHLDA2 siRNA (Human)

CAT: 1601-CRH4962-01Size: 15 nmolDry Ice: NoHazardous: No
CAT#:1601-CRH4962-01Size:15 nmol
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
SiRNA to inhibit PHLDA2 expression using RNA interference
Product Name Alternative
BWR1C; HLDA2; IPL; TSSC3; Pleckstrin homology-like domain family A member 2; Beckwith-Wiedemann syndrome chromosomal region 1 candidate gene C protein; Imprinted in placenta and liver protein; Tumor-suppressing STF cDNA 3 protein; Tumor-suppressing subchromosomal transferable fragment candidate gene 3 protein; p17-Beckwith-Wiedemann region 1 C; p17-BWR1C
Reactivity
H
Source
Synthetic
Applications
RNAi
Purity
> 97%
Form
Lyophilized powder
Components
We offers pre-designed sets of 3 different target-specific siRNA oligo duplexes of human PHLDA2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot.
Storage Conditions
Shipped at 4 °C. Store at -20 °C for one year.
Specificity
PHLDA2 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
NCBI Gene Symbol
PHLDA2
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
SwissProt (Human)
Q53GA4
Entrez GeneHuman
7262

Popular Products